214286-72-3

Upstream product

• 179617-47-1 trans-6-methyl-hept-4-enoic acid ethyl ester 
• 214286-38-1 trans-(1'R,2'R)-6-methylhept-4-enoic acid (2'-hydroxy-1'-methyl-2-phenylethyl)methyl amide 
• 112375-59-4 trans-6-methylhept-4-enoic acid chloride 
• 61229-07-0 trans-6-methylhept-4-enoic acid 

Downstream Products

• 214286-77-8 (E)-(S)-4-[(2R,5S)-5-Cyclopentylsulfanylcarbonylamino-6-methyl-4-oxo-2-(4-trifluoromethyl-benzyl)-heptanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-75-6 (E)-(S)-4-[(2R,5S)-5-tert-Butoxycarbonylamino-6-methyl-4-oxo-2-(4-trifluoromethyl-benzyl)-heptanoylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 214286-74-5 {(S)-2-Methyl-1-[(2S,4R)-5-oxo-4-(4-trifluoromethyl-benzyl)-tetrahydro-furan-2-yl]-propyl}-carbamic acid tert-butyl ester 
• 214286-73-4 (3R,5S)-5-((S)-1-Azido-2-methyl-propyl)-3-(4-trifluoromethyl-benzyl)-dihydro-furan-2-one 

Relevant academic research and scientific papers

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics

The structure-based design, chemical synthesis, and biological evaluation of various ketomethylene-containing human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of a peptidomimetic binding determinant and an e